Implementation of Rapid Drug Desensitization in Antineoplastic Drug Therapy in Denmark Using One‐Bag Protocols

TL;DR

Danish cancer patients with drug allergies successfully continued treatment using rapid desensitization protocols, with most reactions being mild.

Contribution

This is the first implementation of rapid drug desensitization in Northern Europe for antineoplastic drug hypersensitivity.

Findings

60 patients underwent successful rapid drug desensitization with 247 out of 248 procedures completed.

53% of patients experienced mild to moderate breakthrough reactions during desensitization.

96% of desensitization procedures lasted under 6 hours.

Abstract

Rapid drug desensitization (RDD) is the cornerstone of managing patients with immediate drug hypersensitivity reactions (IDHR) to antineoplastic drugs in Southern Europe and the United States. As the first in Northern Europe, an allergy treatment program that includes RDD and drug provocation testing (DPT) was implemented for Danish patients with cancer. We report the results of this allergy intervention, the number of successful treatments, the fraction, timing and severity of breakthrough reactions (BTR) and the actual treatment duration of RDD procedures.

This was a prospective observational study. Patients with IDHRs to antineoplastic drugs referred to the allergy treatment program were included. Patients were followed up until finalization of DPT and/or RDD. RDDs were performed according to one‐bag RDD‐protocols with drug concentrations strictly following manufacturer's instructions and infusion sets primed with flushing fluid. The outcome of DPTs and RDDs were recorded together with detailed information on BTRs and treatment duration of RDD‐procedures.

During 28 months, 72 patients were included. With DPT, a safe drug alternative was found for five drugs, hypersensitivity was ruled out for six, and one treatment was discontinued after a positive DPT. RDD was performed in 60 patients. Of 248 initiated RDD procedures, 247 were completed. BTRs were observed in 53% of patients and 27% of RDD‐procedures, with most BTRs being mild to moderate. The treatment duration was below 6 hours in 96% of RDD procedures.

The allergy treatment program, which included DPT and one‐bag RDD‐protocols, allowed patients to continue critical antineoplastic treatments despite IDHRs.

Figures